Enliven Therapeutics
ELVN
35 hedge funds and large institutions have $33.6M invested in Enliven Therapeutics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 8 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
0.37% less ownership
Funds ownership: 14.59% → 14.22% (-0.37%)
8% less funds holding
Funds holding: 38 → 35 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
46% less capital invested
Capital invested by funds: $61.8M → $33.6M (-$28.2M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $33K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$2.64M |
| 2 |
PVI
Pura Vida Investments
New York
|
+$641K |
| 3 |
Renaissance Technologies
New York
|
+$542K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$512K |
| 5 |
Morgan Stanley
New York
|
+$132K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lion Point Capital
New York
|
-$3.4M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$1.41M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$985K |
| 4 |
Walleye Capital
New York
|
-$297K |
| 5 |
Walleye Trading
New York
|
-$176K |
ELVN Hedge Fund Activity: Q4 2021 in Review
35 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q4 2021, worth a combined $33.6M — down 46% from $61.8M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ELVN and 5 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 12 added.
The largest buyer was Goldman Sachs, adding an estimated $2.64M. The largest seller was Lion Point Capital, exiting entirely with an estimated $3.4M sold.
- 35 institutional investors held Enliven Therapeutics (ELVN) as of Q4 2021, down from 38 in Q3 2021.
- Funds reported $33.6M of Enliven Therapeutics stock for Q4 2021, down 46% quarter-over-quarter.
- 5 funds opened new Enliven Therapeutics positions in Q4 2021 and 8 closed out, a net change of -3 holders.
- The largest Enliven Therapeutics buyer in Q4 2021 was Goldman Sachs, an estimated $2.64M added.
- The largest Enliven Therapeutics seller in Q4 2021 was Lion Point Capital, an estimated $3.4M sold.
Based on aggregated 13F filings for Q4 2021.